Most patients are found in advanced stages because of their asymptomatic nature and usually have a poor prognosis.[3] Although molecular biomarkers such as carcinoembryonic antigen (CEA) and carbohydrate 19-9 (CA19.9) are associated with early diagnosis and prognostic assessment of colon cancer, they are not currently used in clinical practice as they are unreliable.[4] Therefore, novel biomarkers need to be identified and applied to the diagnosis or treatment of colon cancer. This evidence concerns the gene CEACAM5 and colonic neoplasm.